For Manuscript Submission, Check or Review Login please go to Submission Websites List.
For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.
Complex Regulation and Function of the Inflammatory Smooth Muscle Cell Phenotype in AtherosclerosisOrr A.W.a · Hastings N.E.b · Blackman B.R.c, e · Wamhoff B.R.c–e
aDepartment of Pathology, Louisiana State University Health Sciences Center, Shreveport, La., bHemoShear, LLC, and Departments of cBiomedical Engineering and dMedicine, and eRobert M. Berne Cardiovascular Research Center, University of Virginia, Charlottesville, Va., USA Corresponding Author
Prof. Brian R. Wamhoff
Department of Biomedical Engineering
University of Virginia, MR4 RM6022
409 Lane Road, Charlottesville, VA 22908 (USA)
Tel. +1 434 243 6525, Fax +1 434 982 0055, E-Mail email@example.com
Vascular smooth muscle cell (SMC) phenotypic modulation plays a key role in atherosclerosis and is classically defined as a switch from a ‘contractile’ phenotype to a ‘synthetic’ phenotype, whereby genes that define the contractile SMC phenotype are suppressed and proliferation and/or migratory mechanisms are induced. There is also evidence that SMCs may take on a ‘proinflammatory’ phenotype, whereby SMCs secrete cytokines and express cell adhesion molecules, e.g. IL-8, IL-6, and VCAM-1, respectively, which may functionally regulate monocyte and macrophage adhesion and other processes during atherosclerosis. Factors that drive the inflammatory phenotype are not limited to cytokines but also include hemodynamic forces imposed on the blood vessel wall and intimate interaction of endothelial cells with SMCs, as well as changes in matrix composition in the vessel wall. However, it is critical to recognize that our understanding of the complex interaction of these multiple signal inputs has only recently begun to shed light on mechanisms that regulate the inflammatory SMC phenotype, primarily through models that attempt to recreate this environment ex vivo. The goal of this review is to summarize our current knowledge in this area and identify some of the key unresolved challenges and questions requiring further study.
© 2009 S. Karger AG, Basel
The vascular smooth muscle cell (SMC) possesses rather remarkable plasticity, being able to undergo phenotypic modulation during embryonic development, maturation of the adult blood vessels, and in response to many environmental cues that often underlie vascular diseases such as atherosclerosis, in-stent restenosis, aneurysms, and tumor angiogenesis. If only for the economy of language, SMC phenotypic modulation is still classically described in the literature as a shift (sometimes a continuum) between a ‘contractile’ and ‘synthetic’ phenotype. Over the past 30 years, extraordinary progress has been made to further our understanding of the molecular mechanisms that regulate vascular SMC phenotypic modulation, including differentiation to a contractile state, de-differentiation, proliferation, and migration. In atherosclerosis, transition of SMCs from a contractile state to a proliferative and migratory state contributes to plaque growth. SMCs are also responsible for the formation of the fibrotic cap that can stabilize and prevent plaque rupture. Extensive reviews have been written on these topics and will not be discussed herein; we refer you to previous publications [1,2] as a starting point. Inflammation plays a very important role in atherosclerosis. In fact, many would argue that atherosclerosis begins with activation of the endothelium, which includes an inflammatory response. As the disease progresses, vascular SMCs are in proximity to and physically interact with inflammatory cell types, e.g. monocytes and macrophages, which play a very important role in further exacerbating the disease (fig. 1a) . Furthermore, histological images have shown that prior to the onset of complex plaque development in human tissues [4,5] and experimental models of atherosclerosis, markers of inflammation are observed in SMCs in the media of the vessel wall, such as VCAM-1 (fig. 1b, c, respectively) and inflammatory transcriptional mediators, such as activated NF-ĸB [6,7]. What is this SMC phenotype? Although there has not been a rigorous molecular phenotyping of these cells in vivo, it has been shown that SMCs which appear to be resident in the vascular media, neither proliferating nor migrating, can still express contractile markers of differentiation, e.g. α-smooth muscle actin, as well as inflammatory genes such as VCAM-1. Is this phenotype truly distinct or a component of the continuum of SMC-phenotypic modulation between the contractile and synthetic states? The focus of this review is to provide an overview of the current state of knowledge of molecular mechanisms/processes that control the inflammatory SMC phenotype and the function of the inflammatory SMC phenotype in atherosclerosis. We wish to apologize in advance to our many outstanding colleagues whose work we may have either inadvertently overlooked or been unable to discuss in sufficient detail due to space constraints.
Multiple stimuli within the atherosclerotic plaque are capable of promoting an inflammatory phenotype in SMCs. Hypercholesterolemia and dyslipidemia promote low density lipoprotein (LDL) accumulation within the vessel wall. In the setting of enhanced reactive oxygen species production, LDL becomes oxidized (oxLDL) enhancing its proinflammatory properties in endothelial cells, SMCs and monocytes . While atherosclerotic progression is closely linked to systemic environmental risk factors, the local susceptibility of the vasculature to atherosclerosis is controlled by blood flow patterns [9,10]. Vascular regions exposed to unidirectional laminar flow are protected from plaque development, whereas regions exposed to disturbed flow patterns, such as bifurcations, branch points, and curvatures, are prone to develop atherosclerotic plaques. The endothelial cells lining the vessel wall respond to the forces generated by blood flow, and the subsequent endothelial cell response to flow depends upon the specific flow pattern. Laminar flow patterns with high levels of time-averaged shear stresses promote endothelial production of NO and PGI2 inducing both vasodilatory and anti-inflammatory responses in SMCs. In contrast, disturbed flow patterns, marked by low levels of time-averaged shear stresses, promote endothelial cells to adopt a proinflammatory phenotype with enhanced expression of chemokines (e.g. IL-8 and MCP-1) and cell adhesion molecules (e.g. VCAM-1 and ICAM-1; fig. 2.1). The local expression of cell adhesion molecules and chemokines on the endothelial cell surface recruits blood monocytes that produce cytokines such as TNFα and IL-1β further propagating local inflammation . Indeed, the importance of hemodynamic forces regulating the endothelium has been studied for over 20 years. As discussed below, recent studies by our group showed that induction of endothelial cell inflammation by disturbed hemodynamic forces plays a critical role in regulating SMC inflammation [5,12]. In addition to soluble factors, the local SMC environment can significantly affect the inflammatory response. Increased blood pressure in response to hypertension enhances the circumferential strain on SMCs through interactions between the SMCs and the surrounding matrix. In addition, changes in blood pressure affect local hemodynamics, regulating the SMC phenotype through changes in endothelial cell physiology . Alterations in either the mechanical load or the content of the extracellular matrix also modulate proinflammatory gene expression [14,15,16]. Therefore, the induction of the inflammatory SMC phenotype is likely multifactorial, ascribed to the combined and often synergistic effects of multiple inflammatory stimuli, as discussed further in this section.
Proinflammatory stimuli, such as cytokines, oxLDL, Toll-like receptor ligands, and certain matrix proteins, all stimulate inflammatory gene expression through a remarkably conserved set of signaling pathways, including the stress-activated protein kinases p38 and JNK and the transcription factors NF-ĸB, NFAT and STAT1/3 . While p38 signaling appears to play a major role in posttranscriptional regulation of inflammatory genes , JNK signaling stimulates proinflammatory gene expression through effects on transcription factors, most notably AP-1 . Signaling through JNK is implicated in smooth muscle growth , apoptosis , migration , and the expression of proinflammatory genes such as VCAM-1  and MCP-1 . NF-ĸB refers to a family of heterodimeric transcription factors that regulate the expression of genes involved in inflammation, apoptosis, and proliferation. SMCs show constitutive binding of a p50-p50 homodimer to DNA, and this interaction has been shown to repress proinflammatory gene expression in multiple cell types [24,25]. Upon stimulation with proinflammatory cytokines, the p65-p50 heterodimer binds to target DNA stimulating gene expression . Activated NF-kB has been observed in SMCs in both spontaneous atherosclerosis and after vessel injury [6,7], and inhibiting NF-ĸB reduces SMC proliferation in culture and neointima formation after balloon angioplasty . Members of the NFAT family of transcription factors are typically maintained in an inactive phosphorylated state in the cytosol. Activation of the Ca2+-sensitive phosphatase calcineurin dephosphorylates NFAT to stimulate nuclear translocation and NFAT-dependent gene expression . The major roles ascribed to NFAT in SMCs are the induction of proliferation and cell migration [27,28,29], and NFAT inhibition results in decreased injury-induced neointima formation . While activation of the NFAT pathway is implicated in proinflammatory gene expression in other cell types, the role of NFAT in SMC inflammatory gene expression has received little attention thus far. However, NFAT activation is associated with the SMC expression of VCAM-1 and the proinflammatory cytokine IL-6 in vitro suggesting NFAT signaling is involved in the transition to an inflammatory SMC phenotype [14,31,32,33]. While activation of the JAK-STAT pathway is classically associated with cytokine receptor signaling, growth factor receptors, integrins, and G-protein-coupled receptors are also capable of activating JAK-STAT signaling. In SMCs, the ability of angiotensin (Ang) II to stimulate SMC proliferation and migration is dependent upon JAK-STAT signaling [34,35]. While expression in healthy vessels is low, vascular injury results in a significant upregulation of JAK2 and STAT3 . The JAK2 inhibitor AG490 is sufficient to reduce SMC proliferation and neointima formation . In addition to effects on proliferation and migration, STAT3 is implicated in Ang II-induced expression of the IL-18 receptor  and in the IL-6-induced expression of MCP-1 , suggesting a role for JAK-STAT signaling in establishing the inflammatory SMC phenotype.
One mechanism that induces SMC transition to an inflammatory phenotype is through oxLDL. Treating SMCs in culture with oxLDL stimulates the expression of chemokines (MCP-1 and CXCL1) [39,40], cytokines (TNFα)  and cell adhesion molecules (VCAM-1)  propagating the local inflammatory response. The oxLDL-induced expression of TNFα works in an autocrine fashion to induce the NF-ĸB-dependent expression of CXCL1 . In addition to oxLDL-dependent cytokine production, the ability of SMCs to respond to oxLDL may be affected by proinflammatory cytokines since both IL-1β and TNFα stimulate the expression of the lectin-like oxLDL receptor (LOX-1; fig. 2.2) . Recently, work by Miyoshi et al.  demonstrated that the responsiveness of SMCs to oxLDL is dependent upon the specific mouse strain. C57Bl/6J mice are susceptible to diet- and injury-induced plaque formation, while the C3H strain is resistant to the formation of atherosclerotic plaques . Although smooth muscle cells from both strains show an equal ability to oxidize LDL, the oxLDL-induced expression of MCP-1 and VCAM-1 is significantly enhanced in C57Bl/6J SMCs . Therefore, the differential ability of oxLDL to promote the inflammatory smooth muscle phenotype between two mouse strains mimics their susceptibility to atherosclerotic plaque formation. Oxidized phospholipids, such as oxPOVPC that accumulates in atherosclerotic lesions, repress SMC differentiation while increasing type VIII collagen (Col8a1) and inflammatory mediators such as MCP-1 and MCP-3 in both in vitro and in vivo model systems [43,44].
The enhanced production of proinflammatory cytokines in atherosclerosis and the effect of cytokine signaling on SMC growth and migration have been well described elsewhere [reviewed in ref. [45,46]]. For example, IL-1β, TNFα, and IL-8 have been shown to induce both growth and/or migration in human and rodent vascular SMCs under various cell culture conditions. As discussed later, though, SMC responses to cytokine treatment are context dependent, and depending on the cell culture conditions, results from groups can often be opposite. For example, Yue et al.  showed that IL-8 induces human SMC proliferation and migration whereas our group showed no growth or migratory response in human SMCs to IL-8 . However different these functional responses, proinflammatory cytokines also promote SMCs to adopt a proinflammatory phenotype resulting in propagation of the local inflammatory response. Both IL-1β and TNFα stimulate the production of chemokines in SMCs, including IL-8 and MCP-1 [48,49,50], which promote the recruitment of T cells and monocytes into the growing plaque. Furthermore, SMCs express the MCP-1 receptor CCR-2  and addition of exogenous MCP-1 to SMC cultures in vitro results in the NF-ĸB-dependent release of IL-6 . IL-1β and TNFα stimulate the NF-ĸB-dependent expression of the cell adhesion molecules ICAM-1 and VCAM-1 resulting in enhanced adhesion between SMCs and monocytes [53,54,55]. In contrast, IL-4 induces VCAM expression through an NF-ĸB-independent pathway , suggesting that alternative inflammatory signaling pathways can stimulate cell adhesion molecule expression. The interaction between monocytes and SMCs is sufficient to stimulate the expression of IL-6 and MCP-1 , suggesting that cell adhesion molecule expression in the SMC layer may propagate the local inflammatory response.
While most current research analyzes the cellular response to a single stimulus in culture, cells in vivo are exposed to multiple stimuli simultaneously and must adjust cellular responses to account for the whole of environmental stimuli. This point cannot be overstated and caution should be taken when interpreting results from monoculture studies, which are sometimes misleading. Therefore, it is not surprising that crosstalk between individual stimuli can significantly affect the SMC inflammatory phenotype. Both Ang II and activation of the thromboxane receptor synergizes with IL-1β to enhance VCAM-1 expression [22,58]. In the case of Ang II, this effect is gene specific as IL-1β-induced iNOS expression is inhibited by Ang II treatment  through a p38-dependent reduction in iNOS mRNA associated with reduced NF-ĸB activation. In contrast to Ang II, activation of the thromboxane receptor stimulates VCAM-1 expression through the JNK-dependent activation of the AP-1 transcription factor . Activation of protein kinase A (PKA) by various mediators is generally associated with reduced inflammatory gene expression [59,60]. Activators of adenylate cyclase that produce cAMP to activate PKA inhibit the induction of ICAM-1 and VCAM-1 in SMCs by both TNFα and IL-1β . Apolipoprotein E (ApoE) blocks IL-1β-induced iNOS and COX-2 expression through the PKA-dependent inhibition of NF-ĸB and AP-1 . Ligation of certain nuclear receptors, such as the estrogen receptor  or PPARγ , reduces proinflammatory gene expression as well. For the estrogen receptor, this reduction results from competition with NF-ĸB for binding to the transcriptional coactivator p300 . While these studies suggest ordered communication between environmental signaling cues, the bevy of potential relationships and the precise mechanisms underlying this communication remain unknown.
The composition of the smooth muscle matrix affects multiple aspects of SMC function. SMC are normally surrounded by a basal lamina composed of collagen IV, laminin, and perlecan, and signals generated by the basal lamina prevent SMC growth and stimulate differentiation [65,66] (fig. 2.3). In contrast, transitional matrix proteins such as fibronectin (FN) and osteopontin are deposited in the vessel wall during injury, and these transitional matrix proteins stimulate SMC growth through the ERK-dependent expression of cell cycle regulators [65,66]. However, recent work suggests matrix composition may similarly effect the transition to the inflammatory phenotype. TNFα and IL-1β both stimulate SMC FN expression , and attachment to FN stimulates transient activation of NF-ĸB . Osteopontin deposition is enhanced in the atherosclerotic plaque, and osteopontin siRNA reduces Ang II-dependent secretion of IL-6 through an NF-ĸB- and AP-1-dependent mechanism . Matrix-specific cellular responses are thought to occur through the integrin family of matrix receptors. The integrins α5β1 and αvβ3 are associated with binding to these transitional matrix proteins and are implicated in the enhanced proliferation and migration associated with wound-induced neointima formation [70,71]. These integrins also stimulate NF-ĸB activation in other cell types [72,73], but their role in SMC inflammation remains relatively unexplored. In contrast, the non-integrin matrix receptor CD44 is implicated in the transition to a proinflammatory phenotype. CD44 binds to hyaluronic acid in the matrix, which shows higher expression in the atherosclerotic plaque . Hyaluronic acid stimulates SMC VCAM-1 expression, and CD44 deficiency reduces atherosclerosis and VCAM-1 expression in the ApoE knockout mouse .
The role of the interstitial matrix in SMC biology is more complex than the protective basal laminae and the proinflammatory transitional matrix. While present under healthy conditions, SMC interaction with the interstitial matrix is thought to occur after the pericellular basal lamina has been degraded. In atherosclerosis, SMCs express collagen I and collagen III contributing to the local fibrotic response in the plaque. Polymerized collagen I reduces SMC growth and migration and is generally associated with a differentiated SMC phenotype [65,75]. In contrast, monomeric collagen I reduces SMC differentiation and promotes an inflammatory phenotype [14,76]. Activation of NF-ĸB in SMCs results in the expression of MMP-1, MMP-3, and MMP-9 that degrade the polymerized collagen fibrils releasing monomeric collagen . Adhesion to monomeric collagen I results in a marked and sustained increase in VCAM-1 expression compared to cells on the basal lamina-associated collagen IV . Unlike cytokines that appear to stimulate VCAM-1 expression through an NF-ĸB-dependent pathway, collagen I-induced VCAM-1 expression is insensitive to NF-ĸB inhibitors . Paradoxically, the induction of VCAM-1 on collagen I requires the NF-ĸB binding site. Recent work by Minami et al.  demonstrated that the NF-ĸB binding sites on the VCAM-1 promoter can also bind to the transcription factor NFAT. Monomeric collagen I stimulates a rapid (<24 h) increase in NFAT activation compared to collagen IV, and the calcineurin inhibitors cyclosporin A and A-285222  both completely block collagen I-induced VCAM expression . These data suggest that matrix composition and soluble cytokines promote VCAM-1 expression through different mechanisms (fig. 2.3).
One remaining question in collagen-induced VCAM-1 expression is the identity of the receptors involved. Collagen I and collagen IV bind to similar integrins, although α2β1 integrins show preference for collagen I while α1β1 integrins preferentially bind to collagen IV . Interestingly, ligation of α2β1 by the snake venom toxin aggretin was recently shown to stimulate SMC growth and migration through the activation of NF-ĸB . In addition, healthy SMCs show high levels of α1β1 expression, while both in vitro and in vivo model systems demonstrate enhanced α2β1 expression in SMCs during phenotypic modulation . The discoidin domain receptors DDR1 and DDR2 are transmembrane collagen receptors, and therefore may also mediate the differential effects of collagen I and collagen IV. Mice deficient in DDR1 show reduced SMC migration to collagen I and reduced expression of MMP-2 and MMP-9 . Interestingly, mice deficient in both DDR1 and the LDL receptor show reduced atherosclerosis compared to LDL receptor null mice, characterized by reduced macrophage content within the plaque . More work will be required to define the specific receptors and molecular mechanisms underlying the collagen I-induced transition to the inflammatory phenotype (fig. 2.3).
As we stated above, caution must be taken when interpreting monoculture cell studies and single stimuli. Cells dispersed from organs rarely behave like they do in vivoand the cell phenotype in vivo is often dictated by many factors. In the vasculature, elegant studies from the Gimbrone Laboratory (Brigham and Women’s Hospital) and others have shown that the pulsatile nature of blood flow and the forces imposed on the endothelium can recapitulate endothelial cell phenotype ex vivo [9,84]. Flowing blood generates a tangential frictional force termed shear stress that endothelial cells respond to. Endothelial cells exposed to shear stress produce multiple factors that are known to promote SMC migration in SMC monoculture studies, such as PDGF-BB and IL-1α . As mentioned previously, in humans and animal models, atherosclerosis preferentially develops in regions of the vasculature where hemodynamic shear forces are disturbed, including regions where arteries bifurcate, e.g. the carotid sinus, and areas of extreme curvature, e.g. the inner region of the aortic arch. To illustrate the importance of region-specific hemodynamic shear forces in regulating cell phenotype, Dai et al.  generated hemodynamic flow patterns from human subjects where atherosclerosis develops and flow is disturbed (the carotid sinus) and where atherosclerosis does not develop and shear forces are high (the common carotid artery), and applied these wave forms to endothelial cells in cell culture using a cone and plate viscometer [86,87]. Results from these studies showed that disturbed hemodynamic flow induces endothelial priming towards inflammation, whereas high pulsatile shear stress patterns promote the quiescent endothelial cell phenotype (fig. 2.1).
Recently our group showed that when human endothelial cells are grown in coculture with SMCs, application of an atheroprone, carotid sinus flow increases IL-8 secretion from endothelial cells which was associated with an increase in VCAM-1 expression in both endothelial cells and SMCs . When monocytes were introduced into the system, increased monocyte adhesion was observed in both endothelial cells and SMCs exposed to disturbed hemodynamic waveforms compared to atheroprotective waveforms. Further analysis of the role of endothelial-derived IL-8 in the SMC expression of VCAM-1 demonstrated a surprising anti-inflammatory role for IL-8 (fig. 2.4). Blocking IL-8 secretion from the endothelium by either siRNA or anti-IL-8 prevented flow-induced secretion of IL-8 and potentiated flow-induced endothelial and SMC VCAM-1 expression . Treating SMCs with IL-8 did not induce VCAM-1 expression, while treating cells with both IL-1β and IL-8 reduced VCAM-1 expression compared to cells treated with IL-1β alone. This induction of VCAM-1 by IL-1β requires p38 activity, and IL-8 reduces IL-1β-induced p38 signaling suggesting a potential mode of action . This intricate signaling between the endothelium and SMCs is very difficult to tease out in intact arteries, and furthermore, in rodents, these studies are further challenged by the fact that mice and rats do not express the IL-8 gene.
Other forces, including circumferential strain that affects both endothelial cells and SMCs during the cardiac cycle, can play a role in vascular responses . Experimental analysis of the smooth muscle response to stretch suggests that a certain degree of stretch is required to maintain the differentiated SMC phenotype . However, too little or too much stretch both result in SMC proliferation and the induction of inflammatory genes [15,16]. Exposing vascular SMCs to pulsatile stretch in culture stimulates NF-ĸB activation through an oxidative stress-dependent pathway . Stretch-induced production of reactive oxygen species stimulates MCP-1 expression through an ERK- and p38-dependent mechanism , suggesting stretch may utilize multiple signaling pathways to induce inflammatory gene expression. Vascular SMCs align parallel to the stretching force, and application of uniaxial stretch polarizes Rac activity to mediate this alignment response . Since Rac also stimulates reactive oxygen species production through the NADPH oxidase complex , this remodeling stimulus may similarly be involved in the inflammatory phenotype. As such, Rac signaling is implicated in stretch-induced IL-6 expression through activation of both p38 and NF-ĸB . Interestingly, force-induced SMC alignment is also a function of shear forces on the endothelium [12,94], suggesting that endothelial cells may play an important role in generating the spatial cues necessary to direct SMC-adaptive signaling .
It is now apparent that observations in monoculture studies with single stimuli are only scratching the surface of what may be going on in an intact blood vessel. Because it is very difficult to dissect how multiple signals are integrated in vivo, developing models that attempt to recapitulate human in vivo cell phenotypes ex vivo will allow for a more detailed understanding of the factors and mechanisms that regulate not only SMC phenotype in atherosclerosis, but endothelial cells and macrophages and the delicate interactions in signaling occurring between these cells types (fig. 1, 2).
In addition to transcriptional regulation, protein expression often depends upon multiple posttranscriptional regulatory steps that affect mRNA stability and translation. MicroRNAs are evolutionarily conserved short RNA sequences that function to silence the expression of target genes, either through preventing translation or by inducing degradation. The miR-126 regulates VCAM-1 expression in endothelial cells ; however miR-126 expression in SMCs has not been described. The microRNA miR-155 is emerging as a key regulator of inflammatory gene expression in leukocytes and lymphocytes [96,97]. In leukocytes, expression of miR-155 is induced by lipopolysaccharides, TNFα, and IFN-γ [98,99] and is thought to represent a negative feedback pathway, as miR-155 reduces the expression of components of the TLR and cytokine signaling pathways such as FADD, RIP, and IKK . Smooth muscle cells show constitutive expression of miR-155, and the Ang II type I receptor is translationally repressed by miR-155 in SMCs . However, the relevance of miR-126 and miR-155 to the SMC inflammatory phenotype is currently unknown and should provide an interesting target for future research.
In addition to microRNAs, the presence of adenylate uridylate-rich elements (AREs), usually located in the 3′ untranslated region of mRNAs, regulates mRNA stability by affecting its degradation . Many inflammatory proteins are encoded by ARE-containing mRNAs, including ICAM-1, VCAM-1, TNFα, IL-1β, IL-8, and MCP-1 among others, consistent with the need to rapidly and efficiently modulate the expression of these genes [18,102,103,104]. AREs affect mRNA stability through multiple ARE-binding proteins (i.e. HuR, AUF1, and TTP) that can function to either reduce or enhance the stability of the target mRNA sequences . HuR generally protects ARE-containing transcripts from degradation, while AUF1 and TTP destabilize target mRNA. These effects appear to be gene specific, as AUF1 binding destabilizes IL-3 mRNA  while TTP destabilizes TNFα and GM-CSF mRNA [106,107]. Many of the ARE-binding proteins are regulated by phosphorylation. For example, the stress-activated kinase p38 induces MAPKAP kinase 2 (MK2)-dependent phosphorylation of TTP [108,109] resulting in the recruitment of the 14-3-3 family of adaptor molecules. Binding of 14-3-3 to TTP blocks the interaction with the ‘decay machinery’ and prevents TTP dephosphorylation by protein phosphatase 2α thereby promoting mRNA stability [109,110]. MK2 knockdown suppresses IL-1β-induced VCAM-1 and MCP-1 expression, and the MK2 knockout shows reduced hypercholesterolemia-induced atherosclerosis .
Some inflammatory stimuli appear to specifically target mRNA stability to induce inflammatory gene expression either alone or synergistically with other stimuli. VCAM-1 expression in response to TNFα in synoviocytes can be sustained at the posttranscriptional level by the cotreatment with IL-4 or IL-13 . IL-8 reduces both p38 phosphorylation and VCAM-1 expression in response to IL-1β . However, the role of p38 signaling in VCAM-1 mRNA stability has yet to be explored in this system. We recently demonstrated that collagen I stimulates a sustained increase in VCAM-1 expression, and this effect may also involve posttranscriptional regulation. Plating SMCs on a collagen I matrix results in a rapid (∼6 h) increase in the activity of the VCAM-1 promoter measured using a luciferase construct . However this enhanced activity was reduced to basal levels by 24 h . Despite this, levels of VCAM-1 mRNA and protein continued to climb for at least 5 days. One explanation for this discrepancy is that collagen I promotes VCAM-1 mRNA stability. Activation of p38 and subsequent TTP phosphorylation is one way to accomplish this, however p38 activation was similar between matrices .
Regulation of mRNA translation represents another means of posttranscriptional control. Protein translation is classically regulated by the mammalian target of the rapamycin (mTOR) pathway [recently reviewed in ref. [112,113]]. Binding of eIF-4E to the 5′ mRNA cap recruits eIF-4G to stimulate the formation of the eIF-4F complex and initiate cap-dependent translation. The interaction between eIF-4E and eIF-4G is blocked by 4E-BP1. Phosphorylation of 4E-BP1, most commonly by mTOR, reduces 4E-BP1 binding to eIF-4E thereby enhancing translation. Rapamycin is currently in use as an immunosuppressant due to its potent growth-inhibitory effects. Several inflammatory stimuli activate mTOR, although little is known concerning the role of mTOR in inflammatory gene expression. In response to TNFα, mTOR inhibition blocked the expression of IL-6 but did not affect the expression of IL-8 or MCP-1 . An alternative mechanism of translational regulation is the activation of MAP kinase signal-integrating kinase-1 (Mnk-1), a substrate of both p38 and ERK MAP kinases that phosphorylates eIF-4E on Ser209 enhancing its affinity for the mRNA cap [115,116]. Mouse macrophages require Mnk-dependent eIF-4E phosphorylation for lipopolysaccharide-induced TNFα production . TNFα and IL-1β stimulate eIF-4E phosphorylation through the p38-dependent Mnk1 activation, and Mnk1 inhibition prevents IL-1β and anisomycin-induced release of proinflammatory cytokines, including IL-1β, TNFα, and IL-6 [118,119]. In addition to eIF-4E, Mnk phosphorylates the ARE-binding protein hnRNP A1, and this phosphorylation stabilizes TNFα mRNA in T cells . While a role for Mnk signaling in the SMC inflammatory phenotype has not been described, Mnk proteins are expressed in SMCs and ERK-dependent Mnk-1 activation was shown to be required for angiotensin II-induced SMC protein synthesis and hypertrophy . The involvement of Mnk signaling in SMC inflammatory gene expression is an intriguing target for future research.
Will targeting vascular inflammation reduce atherosclerosis? Agents that block SMC proliferation have been shown to be effective in reducing in-stent restenosis and atherosclerosis, but will this apply to agents that block inflammation? Targeting one inflammatory pathway may be insufficient to reduce the inflammatory phenotype. However, given the importance of p38 signaling in the posttranscriptional control of the inflammatory response, it is not surprising that three p38 inhibitors (SCIO469, VX-702, and BIRB-796) are currently in clinical trials for the treatment of chronic inflammatory diseases such as Crohn’s disease and rheumatoid arthritis [17,122]. Secondary clinical outcomes such as carotid intima media thickness may shed light on whether such therapies can also reduce atherosclerosis. Interestingly, statins, specifically Crestor (rosuvastatin calcium), was recently shown in the Jupiter Trial to reduce C-reactive protein, a biomarker for systemic inflammation, in addition to its primary effect of lowering cholesterol. What is interesting, though, is that there are little data showing that statins decrease vascular wall inflammation in vivo. Thus, although we have presented compelling evidence that the inflammatory SMC phenotype is important in atherosclerosis, therapeutic targeting of this cell type is in its infancy. In fact, to these authors, it is not clear if there are any therapies in development that are designed to directly target the vascular wall for preventing atherosclerosis. All therapies to date decrease atherosclerosis by treating the factors associated with the development of the disease, such as cholesterol, triglycerides, diabetes, and hypertension.
Can vascular inflammation be used to diagnose atherosclerosis? The field of molecular imaging has taken advantage of cell surface markers associated with inflammation, such as VCAM-1, to develop antigen-recognition imaging modalities for diagnosing regions of vascular inflammation and atherosclerosis and potential spatial monitoring of anti-VCAM-1 pharmacotherapy . It is also plausible that small molecule compounds, drug therapies, and gene therapy can be delivered to inflamed blood vessels using VCAM-1 molecular-targeted microbubble/contrast agent carriers [124,125].
Is SMC interaction with macrophages during the development of atherosclerosis good or bad? Endothelial cell interaction with SMCs at the myoendothelial cell junction is very important in regulating tone and vessel homeostasis and healthy cell phenotype. Conventional wisdom would suggest that monocyte/macrophage interaction with SMCs in atherosclerosis is bad but there is no definitive proof of this (fig. 2.5). Studies have shown that SMCs can function to stabilize monocytes/macrophages and prevent apoptosis, a good thing? . Indeed, the inherent plasticity of the vascular SMC is often viewed as a means to repair or heal the vascular wall in response to vascular injury and chemical stimuli. Emerging evidence for a population of anti-inflammatory macrophages (Ly-6Clo monocytes in mouse, CD14+CD16+ monocytes in humans) as negative regulators of atherosclerosis also clouds the predicted function of SMC-dependent macrophage retention model in the progression of atherosclerosis .
Lastly, what are the specific receptors and molecular mechanisms underlying matrix-induced transition to the inflammatory phenotype (fig. 2.3)?
Other major challenges include dissecting out the multiple signaling pathways that regulate vascular SMC phenotype in vivo during the progression of atherosclerosis. It is likely that major progress in this area is going to be dependent on the development of sophisticated loss-of-function approaches including SMC-specific conditional gene knockout models and/or local inhibition of candidate regulatory factors/pathways specifically at sites of lesion formation . These in vivo tasks are not trivial and perhaps the ex vivo coculture models discussed above will allow researchers to further understand these complex mechanisms.
We acknowledge the outstanding support of the University of Virginia Robert M. Berne Cardiovascular Research Center and the Department of Biomedical Engineering and our many good friends and colleagues in the field for their many outstanding studies and creative ideas that we hope have been captured in this review.
This work was supported by NIH grants HL081682 (to B.R.W.), HL082836 and HL080956 (to B.R.B.); the American Heart Association Scientist Development Grant (to B.R.W. and A.W.O.) and the University of Virginia Funds for Excellence in Science and Technology and the Cardiovascular Division Partners’ Fund Award (to B.R.W. and B.R.B.).
Prof. Brian R. Wamhoff
Department of Biomedical Engineering
University of Virginia, MR4 RM6022
409 Lane Road, Charlottesville, VA 22908 (USA)
Tel. +1 434 243 6525, Fax +1 434 982 0055, E-Mail firstname.lastname@example.org
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.